Greatview Aseptic Packaging (HKG:0468) said an independent investigation found no sufficient basis for consolidating its international business following a 2024 restructuring and highlighted significant internal control weaknesses, according to a Thursday filing.
The probe by Grant Thornton also raised concerns over the carve-out of certain overseas units in transaction size tests, which may have been aimed at avoiding shareholder approval requirements.
It further cited inadequate disclosure of related-party transactions and undisclosed purchases of financial products, according to the filing.
The board accepted the findings, saying it will restate its 2024 financials, appoint an internal-control consultant, conduct a second-stage investigation, and pursue legal action to unwind parts of the restructuring.
Trading in Greatview shares, suspended since Feb. 19, remains halted until further notice.
Comments